Armando Santoro - Concepedia

Author

Armando Santoro

Also Known As

A SANTORO, A Santoro, A, Santoro, A. Santoro, A.. Santoro, ARMANDO SANTORO, Aleix Prat, Alessandra Gennari, Alessandro Pulsoni, Alexia Lopes Santoro

1.8K

Publications

76.7K

Citations

120

H-Index

229

Concepts

All Affiliations

Humanitas University IRCCS Humanitas Research Hospital Istituti di Ricovero e Cura a Carattere Scientifico Fondazione Humanitas per la Ricerca Fondazione IRCCS Istituto Nazionale dei Tumori

About

Armando Santoro is an author at Humanitas University specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	73	275	23.3K
2	Health Sciences	45	92	8.5K
3	Engineering	2	2	32
4	Nursing	2	2	35
5	Arts	1	1	32

Armando Santoro

558

Publications

69.9K

Citations

117

H-Index

Page 1

	Year	Citations
Sorafenib in Advanced Hepatocellular Carcinoma Josep M. Llovet, Sergio Ricci, Vincenzo Mazzaferro, New England Journal of Medicine	2008	12.8K
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer David Cunningham, Yves Humblet, Salvatore Siena, New England Journal of Medicine	2004	5K
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer E O’Brien, Nely Wigler, Moshe Inbar, Annals of Oncology Liposomal Doxorubicin HclMetastatic Breast CancerOncologyBreast OncologyPharmacology	2004	1.7K
Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer Alice T. Shaw, Dong-Wan Kim, Ranee Mehra, New England Journal of Medicine	2014	1.4K
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Ghassan K. Abou‐Alfa, Lawrence H. Schwartz, Sergio Ricci, Journal of Clinical Oncology	2006	1.2K
Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Thomas Yau, Yoon‐Koo Kang, Tae‐You Kim, JAMA Oncology	2020	1.2K
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial Anas Younes, Armando Santoro, Margaret A. Shipp, The Lancet Oncology Lymphoid NeoplasiaTransplantationMarrow TransplantationImmunotherapyMedicine	2016	915
Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: Subanalyses of a phase III trial Jordi Bruix, Jean‐Luc Raoul, Morris Sherman, Journal of Hepatology	2012	819
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial Philippe Armand, Andreas Engert, Anas Younes, Journal of Clinical Oncology Cell TherapyRelapsed/refractory ChlImmunologyImmunotherapyHematological Malignancy	2018	734
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial Steven M. Horwitz, Owen A. O’Connor, Barbara Pro, The Lancet	2018	707

Page 1